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Objective: Femorodistal autologous vein bypass proves to be the preferred surgical therapy for long arterial occlusions and
provides excellent early and long-term results in critical lower limb ischemia. Whenever vein length was insufﬁcient and
two distal outﬂow arteries were present, a sequential composite bypass conﬁguration was chosen with human umbilical
vein (HUV) or ovine collagen prosthesis (Omniﬂow II; Bio Nova International Pty Ltd, North Melbourne, Australia) as
the proximal prosthetic part of the bypass. Single-center experience with this technique regarding limb salvage, graft
function, secondary reinterventions, and biodegeneration is presented.
Methods: Between January 1998 and January 2009, 122 consecutive sequential composite bypass operations were per-
formed on 116 patients for short-distance claudication (2), chronic critical ischemia (117), or acute ischemia (3) in the
absence of sufﬁcient autologous vein length. HUVwas used in 90 cases and Omniﬂow II in 32 cases. Grafts were followed
by duplex scan supplemented by angiography in case of recurrent ischemia with prospective documentation of follow-up
data in a computerized vascular database. Retrospective analysis of graft patency, limb salvage, and aneurysmal degen-
eration of the biologic prosthesis was performed.
Results: Mean follow-up was 59 6 45.5 months (range, 1-161 months). The 30-day mortality was 4.1%. Early post-
operative complete or partial bypass thrombosis developed in 16% (20 cases) and required successful revision in 16 cases.
During follow-up, 30 complete and 12 partial bypass occlusions occurred, necessitating selective surgical or interventional
revision. Primary, primary assisted, and secondary patency rates and the limb salvage rate were 48%, 62%, 71%, and 87%,
respectively, after 5 years and 26%, 46%, 54%, and 77%, respectively, after 10 years for all bypasses. Late biodegeneration
of HUV prostheses was detected in four instances.
Conclusions: Late graft patency and limb salvage were good. These factors, combined with a tolerable rate of late aneu-
rysmal degeneration, justify the use of biologic vascular conduits and autologous vein for complex femorodistal
reconstructions. (J Vasc Surg 2014;60:1543-53.)In critical chronic lower limb ischemia, crural or pedal
bypass surgery with autologous vein provides excellent
long-term graft patency and limb salvage. Synthetic or
biologic vascular prostheses must be considered as graft
material when autologous vein is limited. Prosthetic fem-
orodistal bypass still provides unsatisfactory outcome in
terms of patency and limb salvage, although vein patches
or cuffs for speciﬁc anastomotic conﬁgurations yield
improved results.1-3 In historical series, some authors
advocated the sequential anastomotic composite tech-
nique to improve graft outﬂow, combining good-
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://dx.doi.org/10.1016/j.jvs.2014.07.103graft.4-9 Recent studies with polytetraﬂuoroethylene
(PTFE) prostheses showed promising results with respect
to limb salvage and bypass patency even in reopera-
tions.10,11 Promising early results with complex human
umbilical vein (HUV)-vein sequential bypasses have
already been reported by our group.12 Because the
manufacture of HUV was suspended in 2006, the only
biologic vascular conduit currently commercially available
is the modiﬁed glutaraldehyde denatured ovine collagen
prosthesis (Omniﬂow II; Bio Nova International Pty
Ltd, North Melbourne, Australia). The results of a
single-center consecutive series of sequential composite
bypass (SCB) combining autologous vein with HUV or
the Omniﬂow II prosthesis are analyzed.
METHODS
From a total of 2569 infrainguinal bypass operations
documented in a computerized vascular database, all
SCBs performed between January 1998 and January
2009 were identiﬁed. A bypass was classiﬁed as SCB
when its proximal prosthetic part consisted of a biologic
conduit and its distal part of autologous vein anasto-
mosed to two or more distal recipient arteries (n ¼
118) or when, in a reoperation, a biologic conduit was1543
Fig 1. Conﬁguration types of 122 sequential composite bypasses (SCBs) with a biologic prosthesis and autologous
vein: (a) serial anastomoses, (b) bridge technique, (c) jump graft, (d) inverted Y graft with natural bifurcation, and
(e) “secondary bridge.”
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tial vein bypass with preservation of the original sequen-
tial outﬂow anastomoses (n ¼ 4). Patient characteristics
and perioperative and follow-up data were evaluated in
a retrospective analysis.
Operative technique and graft conﬁguration. Ipsi-
lateral or contralateral great saphenous vein was considered
the graft of ﬁrst choice. Veins were assessed with preop-
erative vein mapping if needed. A vein diameter of 3 to
3.5 mm after vein distention was accepted. For as much
suitable vein material as possible to be used, good-quality
vein segments were spliced together if necessary. The
composite conﬁguration was chosen if the length of the
harvested suitable vein was insufﬁcient to reach the best
outﬂow vessel. Patent popliteal or crural artery segments
were integrated in the form of sequential anastomoses.
The conﬁguration of the SCB was chosen according to
the length and conﬁguration of the harvested vein and
the site of the recipient vessels (Fig 1). When the bridge
technique proposed by Deutsch was employed, the two
distal recipient arteries were connected with the vein
segment in an end-to-side technique and the prosthesis
to the proximal part of this bridge in an end-to-side
conﬁguration10 (Fig 1, b). In the case of reoperation
for a failing previous sequential vein graft, the prosthesis
was anastomosed to the intact distal interarterial part of
the vein graft in the form of a “secondary bridge”(Fig 1, e). Vein valves were routinely destroyed with a
modiﬁed Leather retrograde valvulotome (V. Mueller
Care Fusion, San Diego, Calif).
Prostheses were rinsed, followed by instillation of undi-
luted heparin solution (25,000 IU or 50,000 IU) for
15 minutes. Distal anastomoses were constructed with
polypropylene suture (7-0) after routine intravenous
administration of 5000 IU heparin. The common femoral
artery was preferred for the proximal anastomosis. The bio-
prosthesis was placed as gently as possible in a subfascial
layer. A subcutaneous position was chosen only in the
case of heavy scariﬁcation after previous bypass operations.
Protamine was not used routinely.
Graft patency was conﬁrmed intraoperatively with
transit time ﬂow measurement (CardioMed Medi-Stim,
Oslo, Norway; Transonic Systems, Ithaca, NY). Postopera-
tive duplex scan and angiography (magnetic resonance
angiography, digital subtraction angiography, or computed
tomography angiography) before discharge were employed
to document patency and graft conﬁguration. Intravenous
administration of heparin was started postoperatively in
combination with additional temporary dual antiplatelet
medication (aspirin plus ticlopidine or aspirin plus
clopidogrel). Oral anticoagulation with phenprocoumon
(Marcumar) was the preferred long-term antithrombotic
therapy and was started within a few days postoperatively
and continued indeﬁnitely at an international normalized
Table I. Patient demographics, risk factors,
comorbidities, and previous procedures
No. %
Patients 116
Mean age 6 SD (range),
years
74.16 8.5 (53.9-92.7)
Female 49 42.3
Male 67 57.7
Risk factors and comorbidities
Hypertension 107 92.2
Hyperlipidemia 79 68.1
Diabetes mellitus 79 68.1
Nicotine abuse 44 37.9
Coronary artery disease 79 68.1
Cerebrovascular accident 14 12.0
End-stage renal disease 13 11.2
Previous ipsilateral vascular procedures
Surgical revascularizationa 37 30.3
Endovascular procedure 30 24.6
Inﬂow procedure 9 7.3
aOne to four (mean, 1.35) failed surgical revascularization procedures.
Table II. Indications for sequential composite bypass
(SCB) surgery
Indication No. %
Severe disabling claudicationa 2 1.6
Critical limb ischemia 117 96.0
Rest pain 25 20.5
Necrosis or ulceration 92 75.5
Acute ischemiab 3 2.4
Total 122 100
aVery short distance claudication without critical ischemia.
bAcute thrombotic occlusion of popliteal aneurysm with impaired outﬂow in
one case.
Table III. Bypass graft material and graft conﬁgurations
Prosthetic part of bypass No. %
HUV 90 73.7
Diameter 5 mm 45
Diameter 6 mm 45
Omniﬂow II 32 26.3
Diameter 5 mm 1
Diameter 6 mm 31
Venous part of bypassa
Ipsilateral great saphenous vein 97 62.2
Contralateral great saphenous vein 12 7.7
Arm vein 35 22.3
Lesser saphenous vein 9 5.8
Superﬁcial femoral vein 3 2.0
156 100
Bypass conﬁguration
Serial sequential bypass technique 54 44.2
Bridge graft technique 50 41.0
Jump graft technique 9 7.4
Natural venous bifurcation 5 4.1
Secondary bridge graft techniqueb 4 3.3
122 100
HUV, Human umbilical vein.
aA total number of 156 vein segments was used in 122 composite bypasses.
Spliced vein grafts consisting of two or three segments were used in 30
bypasses for the distal autologous part of the composite bypass.
bAnastomosis of the prosthesis to a pre-existing patent distal part of a failing
or failed sequential bypass.
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was started only in the presence of contraindications to
oral anticoagulation.
Patients were enrolled into an indeﬁnite follow-up
scheme with angiologic visits after 3, 6, 12, 18, and
24 months with annual repetitions thereafter. The com-
plete graft length was scanned with duplex ultrasound
at each visit with a linear probe by use of a corrected
Doppler angle for stenoses or dilation. Signiﬁcant high-
grade stenosis was deﬁned as a maximum peak systolic
velocity of >3 m/s. Recommended standards for reports
dealing with lower extremity ischemia were applied.13 A
bypass was regarded as failed in the case of complete oc-
clusion of both the prosthetic and venous parts; in the
case of complete occlusion of the prosthetic part despite
preserved patency of the distal venous part with a patent
interarterial connection; and with complete graft replace-
ment or major amputation despite a patent prosthesis. A
bypass was regarded as patent in the case of patency of
the prosthetic part and unimpaired inﬂow into one of
the two distal anastomoses with occlusion of one distal
anastomosis. Follow-up data were prospectively entered
into a computerized database (ACCESS 2000 for Win-
dows) and retrospectively analyzed (SPSS 21.0 for Win-
dows) with Kaplan-Meier survival test and log-rank
test. The protocol and the informed consent were
approved by the Institutional Review Board according
to the regulations for clinical studies of the ethics com-
mittee of the state of Rhineland-Palatinate, Germany.
RESULTS
Patients, risk factors, and indication for operation.
During an 11-year period, 122 femorodistal SCBs were
constructed in 116 patients in 120 lower limbs (four pa-
tients with bilateral operation and two repeated procedures
with the same technique). Patient characteristics, risk fac-
tors, previous ipsilateral operations, interventions, andinﬂow procedures as well as indications for surgery are
listed in Tables I and II.
HUV was used until September 2006, when its com-
mercial distribution was discontinued. As of October
2006, the Omniﬂow II prosthesis was implanted instead.
The serial sequential technique and the bridge graft tech-
nique were the preferentially used conﬁgurations. In
65.6% of the cases, the most distal anastomosis was located
at the level of the distal calf or foot. Mean operative time
was 260 6 53 (range, 110-390) minutes. A subcutaneous
position for the prosthesis was chosen in eight instances
(6.5%). The major part of the vein was tunneled subcutane-
ously in 36 instances (30%). Graft material, bypass conﬁg-
urations, and locations of arterial and composite
anastomoses are listed in Tables III and IV.
Perioperative (30-day) outcomes. The 30-day mor-
tality was 4.1% (ﬁve patients). Early postoperative partial or
Table IV. Location of bypass anastomoses
No. %
Proximal anastomosis
Common femoral 100 82.0
Inﬂow bypass 2 1.6
Profunda femoris 1 0.8
Superﬁcial femoral 18 14.8
Popliteal 1 0.8
Composite anastomosis
Middle thigh 4 3.3
Distal thigh 24 19.7
Proximal calf 69 56.5
Distal calf 25 20.5
First sequential anastomosis 118
Popliteal artery (below knee in 42 cases) 51 43.2
Proximal portion of tibial artery 24 20.3
Middle and distal portion of tibial artery 43 36.5
Second sequential anastomosisa 119
Proximal and middle portion of tibial artery 39 32.8
Distal portion of tibial artery 28 23.5
Pedal artery 52 43.7
Previous sequential vein graftb 4 3.3
aThree distal anastomoses in one patient.
bSecondary bridge with intercrural connection.
Table V. Early complications and patient outcome
Postoperative (30-day) complications in 122
operations No. %
Death (ischemic heart failure, stroke, sepsis) 5 4.1
Myocardial infarction, cardiac failure, arrhythmia 14 11.5
Stroke, transient ischemic attack 4 3.2
Respiratory failure, pneumonia 5 4.1
Renal failure (reversible) 2 1.6
Sepsis, systemic inﬂammatory signs 7 5.7
Delirium 11 9.0
Others 3 2.5
Combined mortality and morbiditya 30 24.6
Hematoma (surgical revision) 9 (4) 7.3
Wound infection or delayed wound healing 24 19.6
Prosthetic graft infection 3 2.5
Major amputation 3 2.5
Minor amputation 28 23.0
Late patient outcome: mean follow-up,
59 6 45.4 months (1-161 months)
Death (cardiovascular, tumor) 83 71.5
5-year survival (Kaplan-Meier) 48
Major amputation during follow-up 13
aForty-six severe systemic vascular and nonvascular complications in 30
patients.
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(16.4%). Despite occlusion of the most distal anastomosis
in one case, conservative treatment was chosen because of
sufﬁcient foot perfusion. Surgical revision was initiated in
17 cases and restored patency in all but one instance that
necessitated early major amputation. Ten of the success-
fully revised reconstructions failed during follow-up after a
median of 19.5 months. Early postoperative infection of
the prosthesis occurred in two HUV grafts and one
Omniﬂow II prosthesis. Two limbs underwent early major
amputation without graft revision (Table V).
Late outcome. One patient was lost to follow-up and
48 patients (41%) could be followed up for more than
60 months. The 5- and 10-year survival was 45.1% and
16.6% for men and 51.0% and 33.3% for women, with a
better survival for women (P ¼ .045) (Fig 2). During later
follow-up, 13 patients were not able to attend further
scheduled duplex surveillance because of deterioration of
their general state of health. However, information about
the status of the limb that was operated on was obtained
from the attending general practitioner.
One additional bypass infection of an HUV was
detected 3 months after surgery and treated by successful
partial graft replacement.
Failure of the prosthetic part with preserved patency of
both distal anastomoses was found in ﬁve cases. Late occlu-
sion of one of the distal anastomoses with preserved
patency of the biologic prosthesis was noted in 18 cases
(15%), in three cases the ﬁrst distal anastomosis and in 15
the most distal anastomosis. Subsequent complete bypass
failure developed in 33% an average of 34 (3-84) months
after detection of the partial anastomotic occlusion.
All in all, 35 bypasses (28.0%) failed. Asymptomatic
occlusion without any further need for intervention oramputation was diagnosed at the time of routine duplex
scan in eight grafts (6.5%). All other patients presented
with recurrent ischemia. Fourteen grafts underwent single
or multiple revisions to restore patency, but durable
patency could be achieved only in ﬁve grafts. Seven patients
underwent a repeated bypass operation.
Repetitive duplex imaging according to the protocol
was available for 114 grafts (93%). It unmasked signiﬁcant
stenotic lesions in 21 (17.2%) patent grafts, in most in-
stances at the anastomoses or in the venous part of the
bypass after a mean of 45months (3-158months). These le-
sions required 28 additional interventions or operations to
maintain graft patency, leading to durable bypass function
in 19 cases even in very old grafts (Table VI and Fig 3).
Duplex examinations detected aneurysmal dilation of
the prosthetic bypass component in four HUV grafts
(4.4%) after 114, 113, 101, and 95 months, respectively,
in one case combined with a graft stenosis. After a limited
follow-up, no aneurysmal changes have been detected in
Omniﬂow II prostheses up to now.
During follow-up, another 14 major amputations (12
above knee) were necessary, in one instance despite graft
patency (Table VI).
Primary, primary assisted, and secondary patency rates
and the limb salvage rate for HUV sequential bypasses
were 49%, 66%, 74%, and 87%, respectively, after 5 years
and 26%, 49%, 56%, and 77%, respectively, after 10 years.
Primary, primary assisted, and secondary patency rates
and the limb salvage rate for Omniﬂow II sequential
bypasses were 45%, 50%, 62%, and 85% after 4 years
(Figs 4 to 6). There was a trend suggesting a better second-
ary patency for the HUV grafts within the ﬁrst 48 postop-
erative months (P ¼ .09). Bypass patency and limb salvage
were not inﬂuenced by the location of either the composite
Fig 2. Survival of 67 men and 49 women operated on with human umbilical vein (HUV)evein and Omniﬂow IIevein
sequential composite bypasses (SCBs). SE, Standard error.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 6 Neufang et al 1547anastomosis (thigh, proximal or distal calf) or the most
distal bypass anastomosis (proximal and middle calf or
distal calf and foot; P ¼ .46 and P ¼ .74). Limb salvage
was not associated with the type of prosthesis used (P ¼
.56). No signiﬁcant difference for secondary patency and
limb salvage was found for serial sequential anastomoses
or the bridge technique (P ¼ .22 and P ¼ .95). However,
the bridge technique showed signiﬁcantly better results for
primary patency (P ¼ .03).
Anticoagulation. Long-term oral anticoagulation
with phenprocoumon (Marcumar) was regarded as the
optimal anticoagulation and initiated in 104 instances
(85%). It was not started in 18 cases because of periopera-
tive death (ﬁve), poor compliance and poor general status,
end-stage renal insufﬁciency, compliance concerns with
age older than 90 years, or early bypass occlusion with
amputation. Four of the remaining 13 bypasses under
early antiplatelet therapy failed, with the consequence
of amputation. Bleeding complications after oral anti-
coagulation during follow-up were noted in 12%, pre-
dominantly minor bleedings or gastrointestinal bleeding,
and led to a change in the medication to antiplatelets.
Oral anticoagulation was subsequently discontinued in a
further 16% of cases, generally because of poor compliance
or new diagnosis of a malignant tumor. In three of these
instances, the discontinuation of oral anticoagulation
without sufﬁcient alternative antithrombotic medicationcaused occlusion of the complete bypass and major
amputation without evidence of previous bypass stenosis.
DISCUSSION
Autologous vein should be used for all infrainguinal
bypass reconstructions whenever possible.14,15 However,
there is a substantial need for small-diameter vascular pros-
theses in case of insufﬁcient vein. One concept for improve-
ment of long-term bypass graft patency is based on
reduction of distal outﬂow resistance. The concept of
sequential anastomoses was promoted 30 years ago.4-6 It
was based on Jarrett’s experimental work, which showed
a signiﬁcant increase of the ﬂow rate by integration of a sec-
ond arterial outﬂow.16 Preserved partial patency in case of
later occlusion of the distal portion of the reconstruction
was reported to possibly reduce the rate of severe recurrent
ischemia.7 The most frequently described sequential bypass
technique is the jump graft technique with the prosthetic
anastomosis at the popliteal artery and a distal extension
with autologous vein originating from the synthetic graft.
Promising early primary patency rates between 35% and
64% with a limb salvage rate of 64% to 84% were reported
for this technique.11,17-20 Oppat found a poor patency for
PTFE jump grafts of only 20% after 5 years associated with
a high amputation rate in case of graft failure.19 This poor
limb prognosis is conﬁrmed by our results, which indi-
cate a high risk of major amputation on failure of the
Table VI. Early and late graft function and limb salvage in 122 complex sequential bypass grafts: modes of treatment and
success
Early graft failure (<30 days) No. Grafts affected, % Patency restored
Patency
not restored
Late failure despite
initial success
Complete graft occlusion or
intraluminal thrombus with
occlusion of only prosthetic part or
one distal anastomosis
20 16.4 16 4 8
Occlusion of most distal anastomosis
/conservative treatment
1 1
Operative revision performed 17 16 1 9
Thrombectomy alone 7 6 1 4
Thrombectomy, additional AV
ﬁstula distal anastomosis
2 2 0 1
Thrombectomy, patch angioplasty
distal anastomosis
1 1 0 1
Thrombectomy, graft extension to
tibial artery
2 2 0 2
Thrombectomy with partial graft
replacement
4 4 0 1
Partial graft replacement only (new
short vein segment)
1 1 0 0
Failed revision/ major amputation 1
Major amputation without revision 2
Early prosthetic graft infection
(2 HUV, 1 Omniﬂow II)
3 2.4
Graft failures and interventions during
follow-up (>30 days) No. Grafts affected, %
Patency maintained
or restored
Patency
not restored
Late failure
despite initial success
Bypass occlusion 35 28.7 9 26 4
Conservative treatment with
sufﬁcient perfusion
8 0 8 0
Surgical or interventional treatment 14 10 4 5
New bypass 7 0 0 0
Major amputation 14
Amputation after failed revision 4
Amputation without graft revision 9
Amputation with patent bypass 1
Treatment to prevent failure of patent
graft (duplex diagnosis of severe
disease)
21 17.2 21 0 2
Patchplasty proximal anastomosisa 5 5 0 1
Patchplasty distal anastomosis 1 1 0 0
Patchplasty composite anastomosis 1 1 0 0
Patchplasty bypass 1 1 0 0
Partial replacement of venous partb 5 5 0 1
Partial replacement for localized
infection
1 1 0 0
Bypass graft extension 2 2 0 0
PTA bypass (stent) 3 (1) 3 0 0
PTA distal anastomosis 1 1 0 0
Multiple graft revisions (PTA; partial
replacement)
1 1 0 0
AV, Arteriovenous; HUV, human umbilical vein; PTA, percutaneous transluminal angioplasty.
aOne late bypass thrombosis with revision and amputation.
bOne later complete bypass thrombosis with new bypass.
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failure rate might be explained by the fact that patency
of the distal venous part in jump grafts is completely
dependent on a patent prosthetic inﬂow. Therefore,
Roddy suggested a patent artery distal to the prosthetic
anastomosis as the origin for the venous bypass part topreserve the vein graft patency in case of a proximal
prosthetic failure.20 Bastounis reported favorable results
with a 5-year patency of 59% and a limb salvage rate
of 80% for the serial PTFE composite bypass, which
are similar to the ﬁndings in our series.21 The most
recent results for sequential PTFE bypass were provided
Fig 3. Sequential composite bypass (SCB) with human umbilical
vein (HUV) and greater saphenous vein (bridge technique with
three distal anastomoses: popliteal artery, posterior tibial artery,
JOURNAL OF VASCULAR SURGERY
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patency rate of 65% and a 4-year limb salvage rate of
85% with the Deutsch technique.10,22 He also empha-
sized the option of a reoperation with use of the pre-
served venous outﬂow for a new prosthetic graft
anastomosis.22 The bridge technique seems to have the
advantage that a complex revascularization is possible
even if only short residual saphenous vein or an unusual
vein like the superﬁcial femoral vein is available. The
technique is easy as all anastomoses are end to side,
and the course of the prosthesis can be controlled easily.
Except for the jump graft technique and the natural
bifurcation, a preserved patency of the distal intercrural
venous part is possible and may be regarded as a distinct
advantage of sequential bypass conﬁgurations. This pre-
served patent vein segment can be used for a repeated
procedure.8 We found this phenomenon in ﬁve cases.
In two patients, this patent vein segment could be cho-
sen for a proximal prosthetic extension. In three patients,
the leg remained viable without further intervention.
This might be explained by a slightly improved foot
perfusion through the preserved distal interarterial
connection. For this reason, the jump graft and natural
bifurcation technique should not be used preferentially;
in the case of failure, the complete reconstruction will
be occluded.
An overview of clinical series with the respective results
is provided in Table VII.9-12,17-24
Our policy to use a biologic prosthesis in complex
femorodistal bypass surgery was founded on conﬁrmed
superior patency for HUV compared with PTFE in
above-knee femoropopliteal bypass in historical random-
ized trials.25 In addition, excellent late results for above-
and below-knee bypasses were reported by Dardik as well
as by our group with a tolerable rate of late aneurysmal
degeneration.26,27 Our early results for sequential HUV
composite bypass with a 4-year secondary patency of 67%
and a limb salvage rate of 88% were promising.12
Having had such positive experience with the HUV,
we decided to use the ovine collagen Omniﬂow II pros-
thesis as a substitute for the HUV when it became unavai-
lable because it exhibits similar handling and preparation
features. Although the Omniﬂow II prosthesis has been
in clinical use for three decades, only sparse information
about clinical results is available. Excellent early 3-year
patency of 92% for above-knee bypass was reported in
patients with intermittent claudication, but these results
may reﬂect a selection bias of patients with excellent distal
outﬂow.28 An Austrian group reported on more than 270
ovine collagen grafts implanted mostly for limb salvageand dorsalis pedis artery) 158 months postoperatively. Note the
aneurysmal degeneration of the distal part of the HUV with
implanted self-expandable stent in a stenotic HUV segment
(arrows). Patency of all distal anastomoses is unimpaired.
(Reproduced with permission of Peter von Flotow, MD, Depart-
ment of Angiology, Westpfalz Klinikum Kusel, Germany.)
Fig 4. Primary patency in 90 human umbilical vein (HUV)evein and 32 Omniﬂow IIevein sequential composite
bypasses (SCBs). SE, Standard error.
Fig 5. Secondary patency in 90 human umbilical vein (HUV)evein and 32 Omniﬂow IIevein sequential composite
bypasses (SCBs). SE, Standard error.
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Fig 6. Limb salvage in 120 limbs operated on with human umbilical vein (HUV)evein and Omniﬂow IIevein
sequential composite bypasses (SCBs). SE, Standard error.
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bypasses and rather disappointing results for crural recon-
structions with direct anastomosis. However, the authors
classiﬁed the results as superior to those obtained with their
PTFE prosthetic bypasses.29,30 They found no graft infec-
tions and a very low rate of aneurysmal degeneration.
Risk of subsequent amputation. Previous series have
stressed the fact that once such a complex reconstruction
fails, the risk of subsequent limb loss is high.19 We
believe that long-term duplex scan surveillance may detect
a signiﬁcant number of stenotic lesions that threaten graft
patency. In our series, an individualized approach with
endovascular or surgical procedures helped avoid graft
failure in the majority of these cases (19 of 21). Severe
stenosis was detected even in relatively old grafts beyond a
120-month follow-up. For this reason, it is our policy that
duplex scan surveillance for complex reconstructions
should be lifelong, or at least as long as the patient is able to
ambulate.
Problem of biodegradation. Historically, the rate of
biodegeneration for the HUV was as high as 57% after
2 years.31,32 The incidence of graft aneurysms decreased
signiﬁcantly for the more recent implants.33 Our series of
second-generation HUVs in the popliteal position identi-
ﬁed a late aneurysm rate of 7% for grafts with a low
intervention rate of 3.5%. Most of these degenerations
were detected more than 5 years after implantation and did
not cause recurrent limb ischemia.27 More recent rates ofbiodegeneration for the ovine collagen prosthesis are not
available, but it must be speculated that this may become
an issue for grafts with a long-term patency. In our current
series, four cases of biodegeneration in HUVs were found
during late follow-up after a mean of 105 months, all of
them having maintained bypass function. These ﬁndings
reconﬁrm our position that a tendency to late graft
degeneration may be tolerable in biologic grafts in favor of
an excellent long-term function and preserved limb
perfusion. Lifelong duplex scan surveillance seems neces-
sary to correct patency-threatening changes in the bypass
conﬁguration.
Role of anticoagulation. As mentioned, we regarded
indeﬁnite oral anticoagulation as the optimum medical
treatment for the complex bypass reconstructions. This
strategy is supported by older data that found a better
patency for vein bypasses, especially those regarded as at
risk for failure.34,35 Even more recent reports with PTFE
in the distal crural position favor the use of oral anti-
coagulation to enhance patency.36 On the other hand, oral
anticoagulation can be difﬁcult to maintain at the intended
level, especially when compliance problems occur or the
general physical status of the old patients deteriorates. This
problem may be reﬂected by the fear of bleeding compli-
cations that may have inﬂuenced the decision of some
attending general practitioners to discontinue oral anti-
coagulation and explains the rate of 16% for discontinua-
tion of oral anticoagulation during later follow-up. In such
Table VII. Historical and actual data for sequential femorodistal bypass with small-caliber prostheses
Author Year
No. of
bypasses Prosthesis
Graft
conﬁguration
Popliteal
artery
included
At
ankle
or pedal
level
Repeated
procedure
Primary
patency, %
Secondary
patency, %
Limb
salvage, %
Verta 1982 54 PTFE Jump graft Yes Yes Unclear Not given 72.4 (4 years) 78 (4 years)
Flinn 1984 30 PTFE Jump graft Yes Unclear Unclear Not given 80 (2 years) ?
McCarthy 1992 67 PTFE Jump graft Yes Yes >50% 40 (4 years) Not given 70 (4 years)
Chang 1995 55 PTFE Serial
anastomoses
Yes 75% 35 (8 years) 52 (8 years) 65 (8 years)
Alexander 1996 35 PTFE Unclear Yes Unclear Unclear 35 (2 years) 60 (2 years)
Bastounis 1999 21 PTFE Serial
anastomoses
No Unclear No 59 (5 years) Unclear 80 (5 years)
Oppat 1999 102 PTFE Jump graft Yes Unclear Unclear 20 (7 years) Unclear Similar to
patency
Deutsch 2001 45 PTFE Venous bridge No Yes 62% 26 (4 years) 39 (4 years) 45 (4 years)
Roddy 2002 27 PTFE Arterial origin
of distal
vein graft
Yes Yes >90% 64 (3 years) 64 (3 years) 88 (3 years)
Mahmood 2002 68 PTFE Side-by-side
anastomosis
Yes Yes 49% 68 (2 years) 73 (2 years) 75 (2 years)
Neufang 2005 54 HUV Serial
anastomoses,
66%
Venous
bridge, 34%
44% Yes 23% 53 (4 years) 67 (4 years) 88 (4 years)
Gargiulo 2010 25 PTFE Venous bridge 88% Unclear 64% 54 (5 years) 85 (4 years)
Neufang 2014 122 HUV
Ovine
collagen
Various
conﬁgurations
43% 67% 30% 48 (5 years) 71 (5 years) 87 (5 years)
HUV, Human umbilical vein; PTFE, polytetraﬂuoroethylene.
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department seems important for advice on how to best
maintain a sufﬁcient antithrombotic therapy and may
possibly help avoid graft failure and amputation.CONCLUSIONS
The reported patency and limb salvage rates for com-
plex infrainguinal composite bypasses support the further
use of this technique in appropriate cases. Lifelong duplex
scan surveillance combined with patency-maintaining inter-
ventions is effective and leads to a favorable secondary
patency and limb salvage. The use of biologic vascular pros-
theses as the inﬂow part of such constructions is associated
with a durable bypass patency and an acceptable rate of
biodegeneration and therefore seems to be justiﬁed.
Further studies with this technique in patients with unsuit-
able veins are necessary. The risk of biodegeneration for the
Omniﬂow II graft must be an object of ongoing
investigation.
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